SGSumit Gaur

Sumit Gaur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sumit Gaur has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Philipovskiy

    Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, United States of America

    3 shared publications
  • Javier Corral

    Department of Internal Medicine, TTUHSC-El Paso, Paul L Foster School of Medicine, El Paso, TX, U.S.A.

    3 shared publications
  • Alexander Philipovskiy

    Sarah Cannon Research Institute at Florida Cancer Specialists Lake Mary FL USA

    2 shared publications
  • Alireza Torabi

    Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, Texas (Ngamdu, Torabi, Badri, Teleb, Gaur); and the Departments of Internal Medicine (Ngamdu, Badri, Teleb, Gaur), Pathology (Torabi), and Hematology/Oncology (Gaur), University Medical Center, El Paso, Texas

    2 shared publications
  • Attilio Orazi

    Department of Pathology, Texas Tech University Health Sciences Center El Paso, United States of America

    2 shared publications
  • Javier Corral

    TTUHSC, El Paso, TX

    2 shared publications

Latest Publications

  • Open Access

    Clinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004–2022)

    by Manas Pustake, Atharva Railkar, Stevenson Ongsyping, Swarada Joshi, Oboseh Ogedegbe, Mohammad Arfat Ganiyani, Sumit Gaur, Jesus Gomez, Rohan Garje

    Background: Prostate cancer remains one of the most prevalent malignancies and a leading cause of cancer-related mortality among men in the United States, with more than 300,000 new cases diagnosed annually. As the burden of disease continues to rise, ensuring equitable access to effective treatment remains a critical public health priority. Unequal access to definitive surgical management among disadvantaged populations may contribute to preventable morbidity and mortality. Radical prostatectomy is a cornerstone treatment for localized disease; however, its utilization has evolved over time in response to changing screening guidelines, technological advancements, and shifting treatment paradigms. Despite these developments, disparities in access to surgical management persist. Methods: Using the Surveillance, Epidemiology, and End Results database, we conducted a retrospective cohort study evaluating factors associated with radical prostatectomy utilization among 917,194 men with localized or regional prostate cancer diagnosed between 2004 and 2022. Multivariable logistic regression assessed demographic, socioeconomic, and clinical predictors of surgical treatment. Results: Overall, 33.5% of patients underwent radical prostatectomy. Increasing age was strongly associated with lower odds of surgery (OR 0.904 per year, 95% CI 0.903–0.904, p < 0.001), while married patients were significantly more likely to undergo prostatectomy (OR 1.601, 95% CI 1.554–1.649, p < 0.001). Black patients had markedly lower odds of surgery compared with White patients (OR 0.547, 95% CI 0.539–0.555, p < 0.001), whereas Asian/Pacific Islander patients had slightly higher odds (OR 1.082, p < 0.001). More recent year of diagnosis and increasing income were associated with modest reductions in prostatectomy utilization. Conclusions: These findings demonstrate that treatment selection in prostate cancer is influenced not only by disease characteristics but also by sociodemographic factors, highlighting persistent disparities in access to definitive surgical care and the need for targeted interventions to improve equity in treatment delivery.

  • Discordant PET Findings and a High Relapse Rate Characterize Hispanics With Hodgkin’s Lymphoma Treated With ABVD

    by Sumit Gaur, Alexander Philipovskiy, Umeanaeto Onyedika, Anna M. Eiring, Alok K. Dwivedi, Attilio Orazi

    Background: Population-based studies on Hodgkin’s lymphoma (HL) have shown reduced survival in Hispanics and non-Hispanic Blacks compared with non-Hispanic Whites. To better understand the factors contributing to this outcome discrepancy, we retrospectively reviewed the charts of patients with HL diagnosed and treated at a single institution located along the Texas–Mexico border. Patients and Methods: We performed a retrospective chart review of all patients with HL treated at our institution over an 8-year period (2011-2018). The International Prognostic Score was calculated for all patients and results of positron-emission tomography (PET) scans (interim and end of treatment) were also recorded. Variables analyzed included tumor-related findings (stage, subtype of HL), treatment history (chemotherapy regimen including number of cycles, dose intensity and radiation treatments) and neutrophil to lymphocyte ratio. Quantitative variables were described using median, interquartile range, minimum and maximum observations. Categorical variables were described using frequency and proportions. Kaplan–Meier curves were used to show relapse-free survival. Results: A total of 24 patients were treated in the time frame, of whom 23 were Hispanic. All were treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) or an ABVD-like regimen. Dose intensity for chemotherapy exceeded 90%. After a median follow-up of 43 months, the relapse rate was 45.8%. Positive and negative predictive values for interim PET (0% and 50%) and end of therapy PET (80% and 58%) were suboptimal to allow for a PET-adapted therapeutic approach. Conclusion: Hispanics have a high relapse rate following ABVD which is not fully explained by universally accepted prognostic factors. Performance of PET scan in predicting outcomes of HL needs to be further studied and optimized before adopting a PET-adapted treatment paradigm for underserved Hispanic populations.


  • Open Access

    Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)

    by Sundar V. Cherukuri, Amit Sureen, Taylor Infante, Nevetha Rajendran, Osvaldo Padilla, Sumit Gaur

    Primary mediastinal B-cell lymphoma (PMBCL) is a rare subtype of non-Hodgkin's lymphoma. It typically has an aggressive behavior with potential clinical emergencies including cardiac tamponade, thrombosis of major neck vessels, airway obstruction, and tumor lysis syndrome. In this case report, a 38-year-old Caucasian male presented with shortness of breath, a two-month history of 40-pound weight loss, and a left-sided chest wall mass. CT imaging showed a mediastinal mass, measuring 13 × 14.6 × 8.6 cm3, with invasion and partial occlusion of the brachiocephalic veins and upper superior vena cava causing superior vena cava syndrome, and encasement of multiple coronary artery segments. CT-guided biopsy showed high-grade B-cell lymphoma. Cytology biomarkers were positive for CD20, CD45, and PAX5. A trans-thoracic echocardiogram (TTE) was obtained prior to chemotherapy initiation to establish a baseline for cardiac function, which showed an ejection fraction (EF) of 45-50%, right ventricle volume overload and dilation, and pulmonary hypertension. R-CEOP (rituximab, cyclophosphamide, etoposide, vincristine, and prednisone) chemotherapy regimen was initiated and a follow-up echocardiogram after three cycles, revealed a significant improvement in EF; the patient subsequently received three additional cycles of R-EPOCH. Current regimens in the United States utilize dose-adjusted R-EPOCH and R-CHOP, but they must be used cautiously in patients with compromised cardiac function, due to the cardiotoxic side effects of the chemotherapy agent, doxorubicin. This case illustrates that anthracycline-free regimens should be considered in patients with reduced cardiac function, with this case showing the utilization of an anthracycline-free regimen (R-CEOP) for the first three cycles, followed by a transition to R-EPOCH.


  • Incorporating Bortezomib in the Management of Plasmablastic Lymphoma

    by Onyedika Umeanaeto, Joseph Gamboa, Jesus Diaz, M. Nawar Hakim, Javier Corral, Alexander Philipovskiy, Sumit Gaur

    Incorporating bortezomib and/or lenalidomide in the management of plasmablastic lymphoma is an attractive option due to the reported high response rates. However, concerns about overlapping toxicities can deter clinicians from incorporating these novel agents into chemotherapy. In this case report we describe a patient with plasmablastic lymphoma, who received both lenalidomide and bortezomib as part of upfront treatment for a high-risk plasmablastic lymphoma. After completing intensive chemotherapy, the patient was transitioned to a regimen of daily lenalidomide and biweekly bortezomib to decrease the chance of relapse. This maintenance phase was given for 6 months and was well tolerated. Despite having multiple adverse risk factors, the patient remains in remission, 18 months following diagnosis.


  • Outcomes of Hispanic/Latino women with triple-negative breast cancer who achieve a complete pathologic response after neoadjuvant chemotherapy.

    by Alexander Philipovskiy, Javier Chavez Corral, Rosalinda Heydarian, Alok Kumar Dwivedi, Gong Xiaoming, Sajid Leelani, Sumit Gaur

    E12081 Background: The aim of this study was to determine the efficacy of neoadjuvant chemotherapy (NACT) versus adjuvant chemotherapy (ACT) in Hispanic/Latino (H/L) women with triple negative breast cancer (TNBC). Methods: We retrospectively reviewed 104 records of female patients diagnosed with TNBC, stages I–III, treated at Texas Tech Breast Care Center from 2006 to 2016. Pathological complete response (pCR), overall survival (OS) and progression-free survival (PFS) were estimated and compared between two treatment groups. Kaplan Meier survival curve and Cox proportional hazards regression analyses were conducted to determine unadjusted and adjusted effects of NACT compared to ACT. Results: Of 104 TNBC patients with median duration of follow up of 6 (range 2-11) years, 30 (29%) received NACT and 74 (71%) received ACT. Women undergoing NACT were mostly younger, with a mean age of 50.8 (range 40-67) years, compared with those in the ACT group, mean age of 53 (range 32-80) years. Additionally, women in the NACT group had more advanced cancer, stage III (61%) and stage II (33%), in contrast to the ACT group, who had stage III (23%) and stage II (55%). Of 30 patients received NACT,twelve (40%) had pCR. The (median 6 years/range 2-11 years Women who achieved pCR had better PFS and OS compared with patients who received ACT. On the other hand, women with residual cancer after NACT had worse survival outcomes compared with women who received ACT (Hazards Ratio-HR = 0.1, p = 0.001). Conclusions: In our study, we observed that the patients in the NACT group with residual cancer had statistically significantly worse survival outcomes compared with ACT group. Patients who received NACT and had pCR had no relapse over the observation period. Our study suggests that there is a need of a prospective study to better understand the biology of TNBC among H/L women in order to individualized NACT to population of patients with “chemosensitive” subtype of TNBC.

  • Open Access

    Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome

    by Ahmed Alshaban, Osvaldo Padilla, Alexander Philipovskiy, Javier Corral, Meghan McAlice, Sumit Gaur


  • Open Access

    Diffuse Large B-Cell Non-Hodgkin's Lymphoma and Osteosclerotic Myeloma with Features of Poems Syndrome

    by Kyari Sumayin Ngamdu, Alireza Torabi, Nabeel Badri, Mohammed Teleb, Sumit Gaur

    Multiple myeloma is a clonal hematopoietic neoplasm characterized by the proliferation of malignant plasma cells and associated end-organ damage, most notably lytic lesions in the bones. Osteosclerotic myeloma is an unusual variant of the disease in which the skeletal involvement is characterized by sclerotic lesions instead of classical lytic lesions. The disease can be associated with paraneoplastic symptoms, which have been given the acronym POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes). In addition to clonal plasma cell dyscrasias, some cases of POEMS syndrome are associated with Castleman's disease, and in 11% to 30% of the cases both Castleman's disease and clonal plasma cell proliferation are present. POEMS syndrome has rarely been described in patients with non- Hodgkin's lymphoma.


    • 16 November 2014
      • Vol. 28  (6) , 1149-53

    Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor.

    by Sumit Gaur, Ali-Reza Torabi, Javier Corral

    We describe two patients with break point cluster region-Abelsen (BCR-ABL)-positive acute leukemia who had an isolated relapse in the central nervous system (CNS) while receiving a next-generation BCR-ABL inhibitor. The first had B-cell acute lymphoblastic leukemia which relapsed in the CNS while maintaining molecular remission in the bone marrow on nilotinib. The second patient had an isolated CNS myeloid blast crisis of chronic myeloid leukemia while maintaining complete cytogenetic remission in the bone marrow on dasatinib. Mutation analysis of the kinase domain revealed 35 base pair insertion (35INT) between exon 8 and 9 in both cases.